Atara Biotherapeutics (NASDAQ:ATRA) Upgraded to “Hold” at ... Zacks Investment Research upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a sell rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on […] ATRA | Atara Biotherapeutics Inc. Profile | MarketWatch Nov 01, 2019 · Atara Biotherapeutics Inc. company facts, information and stock details by MarketWatch. View atra business summary and other industry information.

Atara Biotherapeutics, Inc. (ATRA) Stock Analysis & News ...

11 Jun 2018 Crowdsourced stock and analyst ratings and analysis for Atara Biotherapeutics, Inc. ($ATRA) from the leading crowdsourced stock rating platform. And, it highly likely that the share price will continue to head further north. This availability information regarding shortable stocks is indicative only and is subject to ATRA, USD, ATARA BIOTHERAPEUTICS INC, Log In to Check Availability CZA, USD, INVESCO ZACKS MID-CAP ETF, Log In to Check Availability.

ATRA | Complete Atara Biotherapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Zacks Investment Research upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a sell rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on […] ATRA | Atara Biotherapeutics Inc. Profile | MarketWatch Nov 01, 2019 · Atara Biotherapeutics Inc. company facts, information and stock details by MarketWatch. View atra business summary and other industry information. Atara Biotherapeutics (NASDAQ:ATRA) Stock Rating Upgraded ...

ATRA News Today (Atara Biotherapeutics) | MarketBeat

Equities analysts forecast that Atara Biotherapeutics Inc (NASDAQ:ATRA) will announce earnings per share (EPS) of ($1.36) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.60) to ($1.15). Zacks: Analysts Expect Atara Biotherapeutics Inc (NASDAQ ... Wall Street analysts expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post earnings per share of ($1.33) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The highest EPS estimate is ($1.29) and the lowest is ($1.37).

Nov 12, 2019 · Atara Biotherapeutics (ATRA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.

Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher Zacks Sep-24-18 04:55PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Zacks: Brokerages Anticipate Atara Biotherapeutics Inc ... Equities analysts forecast that Atara Biotherapeutics Inc (NASDAQ:ATRA) will announce earnings per share (EPS) of ($1.36) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with estimates ranging from ($1.60) to ($1.15). Zacks: Analysts Expect Atara Biotherapeutics Inc (NASDAQ ... Wall Street analysts expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will post earnings per share of ($1.33) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings. The highest EPS estimate is ($1.29) and the lowest is ($1.37). Zacks: Analysts Anticipate Atara Biotherapeutics Inc ... Wall Street brokerages expect that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share (EPS) of ($1.30) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is …

• cryptocurrency 시장은 몇시에 열렸습니까_
• convertir le salaire des usd en gbp
• previsões indianas do mercado de ações para amanhã
• 1 once dargent troy valeur 2020
• precio de las acciones de plata mag
• 하노이 증권 거래소 ceo
• ساعات التداول الأضواء campbelltown
• aihktjq